Immunitas Therapeutics’ $58 Million Series B Financing Round

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Immunitas Therapeutics on the deal.Immunitas Therapeutics, an immuno-oncology biotech company, announced its $58 million Series B financing round. The round will…